Summary
Profile
Financials
Events
Ownership
Options

Company Info

Industry Pharmaceuticals: Major
Sector Health Technology
Employees 105,794
CEO Dr. Vasant Narasimhan
Address Lichtstrasse 35 , Basel, BS 4056
Phone 41.61.324.11.11
Website www.novartis.com

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Competitors

Company Name 3 Month
%Change
1 Year
%Change
Novartis AG -10.31% -3.91%
Pfizer Inc. 12.12% 29.69%
Thermo Fisher Scientific, Inc. 23.10% 45.83%
Novo Nordisk A/S 22.51% 47.50%
Danaher Corp. 21.38% 59.33%

Statement Summary

as of 4:10 ET PM 09/23/2021
Total Assets (MRQ) 124.0 B
Total Liabilities (MRQ) 69.9 B
Shareholders’ Equity (MRQ) 54.1 B
Total Revenue (Annual) 12.9 B
Net Income (Annual) 2.9 B

Earnings And Estimates

as of 4:10 ET PM 09/23/2021

Current Qtr EPS Estimate 1.62
Current FY EPS Estimate 6.36
Long Term EPS Growth Estimate 7.60
Next Expected Earnings Date 10/26/2021

NVS vs S&P 500

as of 09/23/2021
Relative To
S&P 500
NVS
4 Weeks n/a n/a
12 Weeks n/a n/a
YTD n/a n/a

Earnings Surprises

as of 4:10 ET PM 09/23/2021
Fiscal Quarter Estimate Actual Surprise
06/2021 1.56 1.66 +6.73%
03/2021 1.54 1.52 -1.29%
12/2020 1.37 1.34 -1.97%
09/2020 1.45 1.52 +5.18%
06/2020 1.33 1.36 +2.62%
03/2020 1.39 1.56 +12.17%
12/2019 1.31 1.32 +0.38%
09/2019 1.32 1.41 +6.44%

Financial Strength

as of 4:10 ET PM 09/23/2021
Pre-Tax Margin 25.22
Net Margin 35.85
Operating Margin 23.72
Return On Equity 16.68
Return On Assets 7.26
Inventory Turnover (TTM) 2.28
Sales Growth (MRQ) -0.18

Ratios

as of 4:10 PM ET 09/23/2021
Price/Earnings (TTM) 20.83
Price/Book (MRQ) 3.43
Price/Cash Flow (TTM) 13.92
Book Value (MRQ) 24.16
Quick Ratio (MRQ) 0.56
Current Ratio (MRQ) 0.80
Total Debt/Equity (MRQ) 0.66

Short Interest

as of 4:10 PM ET 09/24/2021
% Short - 0.20%
% Remaining Float - 99.80%
Current Last Month
Short Interest Date 08/31/2021 08/13/2021
Short Interest Shares 4,800,039 4,608,885
Short Interest Ratio 2.2 2.7
M Y M Y
Total Assets 0,0.00 0,0.00
Total Liabilities 0,0.00 0,0.00
Total Equity 0,0.00 0,0.00
M Y M Y
Total Revenue 0,0.00 0,0.00
EBT Exc.
Unusual Items
0,0.00 0,0.00
Net Income 0,0.00 0,0.00
M Y M Y
Cash from
Operations
0,0.00 0,0.00
Cash from
Activities
0,0.00 0,0.00
Cash from
Fin. Activities
0,0.00 0,0.00

TOTAL ASSETS

TOTAL LIABILITIES

TOTAL EQUITY

Balance Sheet

M Y
ASSETS
Cash And Equivalents 0,0.00
Receivables 0,0.00
Inventories 0,0.00
Other Current Assets 0,0.00
Total Current Assets 0,0.00
Property, Plant & Equipment, Gross 0,0.00
Accumulated Depreciation & Depletion 0,0.00
Property, Plant & Equipment, Net 0,0.00
Intangibles 0,0.00
Other Non-Current Assets 0,0.00
Total Non-Current Assets 0,0.00
TOTAL ASSETS 0,0.00
Liabilities & Shareholder Equity
Accounts Payable 0,0.00
Short Term Debt 0,0.00
Total Current Liabilities 0,0.00
Long Term Debt 0,0.00
Deferred Income Taxes 0,0.00
Other Non-Current Liabilities 0,0.00
Minority Interest 0,0.00
Total Non-Current Liabilities 0,0.00
Preferred Stock Equity 0,0.00
Common Stock Equity 0,0.00
Common Par 0,0.00
Additional Paid In Capital 0,0.00
Cumulative Translation Adjustment 0,0.00
Retained Earnings 0,0.00
Treasury Stock 0,0.00
Other Equity Adjustments 0,0.00
Total Capitalization 0,0.00
TOTAL EQUITY 0,0.00
TOTAL LIABILITIES & STOCK EQUITY 0,0.00
Total Common Shares Outstanding 0,0.00
Preferred Shares 0,0.00
Treasury Shares 0,0.00
Basic Weighted Shares Outstanding 0,0.00
Diluted Weighted Shares Outstanding 0,0.00
Number Of Employees 0,0.00
Number Of Part-Time Employees 0,0.00

TOTAL REVENUES

EBT Excluding Unusual Items

NET INCOME

Income Statement

M Y
Sales 0,0.00
Cost Of Sales 0,0.00
Gross Operating Profit 0,0.00
Selling, General, And Administrative Expenses 0,0.00
Research & Development 0,0.00
Operating Income Before D & A (EBITDA) 0,0.00
Depreciation & Amortization 0,0.00
Interest Income 0,0.00
Other Income - Net 0,0.00
Special Income / Charges 0,0.00
Total Income Before Interest Expenses (EBIT) 0,0.00
Interest Expense 0,0.00
Pre-Tax Income 0,0.00
Income Taxes 0,0.00
Minority Interest 0,0.00
Net Income From Continuing Operations 0,0.00
Net Income From Discontinued Operations 0,0.00
Net Income From Total Operations 0,0.00
Extraordinary Income/Losses 0,0.00
Income From Cum. Effect Of Acct. Change 0,0.00
Income From Tax Loss Carryforward 0,0.00
Other Gains / Losses 0,0.00
Total Net Income 0,0.00
Normalized Income
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
0,0.00
Preferred Dividends 0,0.00
Net Income Available To Common 0,0.00
Basic EPS From Continuing Ops. 0,0.00
Basic EPS From Discontinued Ops. 0,0.00
Basic EPS From Total Operations 0,0.00
Basic EPS From Extraordinary Inc. 0,0.00
Basic EPS From Cum Effect Of Accounting Change 0,0.00
Basic EPS From Tax Loss Carryf'd. 0,0.00
Basic EPS From Other Gains (Losses) 0,0.00
Basic EPS, Total 0,0.00
Basic Normalized Net Income/Share 0,0.00
EPS From Continuing Ops. 0,0.00
EPS From Discontinued Ops 0,0.00
EPS From Total Ops. 0,0.00
EPS From Extraord. Inc. 0,0.00
EPS From Cum Effect of Accounting Change 0,0.00
EPS From Tax Loss Carfd. 0,0.00
EPS From Other Gains (L) 0,0.00
EPS, Total 0,0.00
Diluted Normalized Net Inc/Shr
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
0,0.00
Dividends Paid Per Share 0,0.00

CASH FROM OPERATIONS

CASH FROM INVESTING ACTIVITIES

CASH FROM FINANCING ACTIVITIES

Cash Flow Statement

M Y
Cash Flow From Operating Activities
Net Income (Loss) 0,0.00
Operating Gains/Losses 0,0.00
Gross Operating Profit 0,0.00
(Increase) Decrease In Receivables 0,0.00
(Increase) Decrease In Inventories 0,0.00
(Increase) Decrease In Other Current Assets 0,0.00
(Decrease) Increase In Other Current Liabilities 0,0.00
(Increase) Decrease In Other Working Capital 0,0.00
Other Non-Cash Items 0,0.00
Net Cash From Continuing Operations 0,0.00
Net Cash From Discontinued Operations 0,0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities 0,0.00
Sale Of Property, Plant & Equipment 0,0.00
Cash Used For Investing Activities
Sale Of Short-Term Investments 0,0.00
Purchases Of Property, Plant & Equipment 0,0.00
Acquisitions 0,0.00
Purchases Of Short-Term Investments 0,0.00
Other Cash From Investing Activities 0,0.00
Cash Provided by Financing Activities
Net Cash From Investing Activities 0,0.00
Issuance Of Debt 0,0.00
Cash Used For Financing Activities
Issuance Of Capital Stock 0,0.00
Repayment Of Long-Term Debt 0,0.00
Repurchase Of Capital Stock 0,0.00
Payment Of Cash Dividends 0,0.00
Other Financing Charges, Net 0,0.00
Net Cash From Financing Activities 0,0.00
Effect Of Exchange Rate Changes 0,0.00
Net Change In Cash & Cash Equivalents 0,0.00

Earnings Estimates

as of 4:10 ET PM 09/23/2021
Current Qtr
(09/2021)
Next Qtr
(12/2021)
Consensus Estimate $1.62 $1.54
# of Estimates 8 8
High Estimate $1.68 $1.60
Low Estimate $1.51 $1.42
Year Ago EPS $0.86 $0.93
Year Over Year Growth Estimate 89.09% 66.35%
Current Yr
(12/2021)
Next Yr
(12/2022)
Consensus Estimate $6.36 $6.82
# of Estimates 19 19
High Estimate $6.93 $7.36
Low Estimate $6.21 $6.42
Year Ago EPS $5.78 $6.36
Year Over Year Growth Estimate 10.05% 7.16%
Current Qtr
(09/2021)
Next Qtr
(12/2021)
Current Year
(12/2021)
Next Year
(12/2022)
Consensus Estimate $1.62 $1.54 $6.36 $6.82
# of Estimates 8 8 19 19
High Estimate $1.68 $1.60 $6.93 $7.36
Low Estimate $1.51 $1.42 $6.21 $6.42
Year Ago EPS $0.86 $0.93 $5.78 $6.36
Year Over Year Growth Estimate 89.09% 66.35% 10.05% 7.16%

Insider Information Summary

as of 08/31/2021
% Insiders - 0.00%
% Remaining Total Shares - 100.00%
Current 1 Month
Net Insider Transaction 0.00 0.00
Shares Bought 0.00 0.00
Shares Sold 0.00 0.00

Insider Activity

Transaction Date Insider/Title Transaction Type Market Value Shares Average Price Current Holdings

LATEST NEWS

Recent Articles from TheStreet

Tesla Lead

Tesla Begins 'Most Intense Delivery Week Ever'

Tesla started a big end-of-quarter delivery push. Production earlier on had slowed due to parts-supply-chain issues.

Stock Market Today - Global Bond Selloff Continues

Treasury Yields Extend Surge, 10-Year Notes Top 1.5%, As Reflation Bets Accelerate

Benchmark 10-year note yields traded past 1.5% for the first time since June Monday, suggesting a resurgent 'reflation trade' that could carry market interest rates higher into the end of the year.

jim-cramer-on-citigroups-downgrade-of-pfizer (3)

Pfizer Stock Rises on Study of Oral Covid-19 Prevention Drug

Pfizer says it will test an oral antiviral designed to prevent Covid-19.

NYSE Lead

Stock Futures Mixed As Oil Rally Boosts Dow, Treasury Yield Surge Clips Tech

A three-year high for oil prices has the Dow trading higher Monday, but rising Treasury yields, and a looming global power crisis, are holding down broader gains on Wall Street.

25Carnival-Victory carnival

Premarket Movers Monday - Carnival, Tesla, Airbnb, Pfizer

Stocks moving in premarket trading Monday include Carnival, Tesla, Airbnb, Pfizer and Occidental Petroleum.

210810SOFR_1600x900

Q&A With ARRC Chairman Tom Wipf: The Shift to Term Secured Overnight Financing Rate

Leading up to June 2023, $225 trillion of LIBOR contracts will transition to SOFR. “We describe it as this barge of liquidity waiting at harbor,” ARRC Chairman Tom Wipf tells us in an interview.

2020 Polestar 1

Polestar Plans Nasdaq SPAC Listing That Values EV Maker At $20 Billion

Polestar, a Swedish EV maker that includes Leonardo DiCaprio as one of its early investors, will go public via a $20 billion SPAC listing on the Nasdaq.

Rolls-Royce Says Business as Usual After Brexit Vote Despite Prior Warnings

Rolls-Royce Beats Raytheon To $2.6 Billion B-52 Engine Contract With U.S. Air Force

British engineering group Rolls-Royce will make new engines for the USAF's B-52 Stratofortress bomber at its U.S. manufacturing base in Indianapolis.

Wall Street Lead

Stocks Mixed, Oil Leaps, Pelosi Gambles and Germany Votes - 5 Things You Must Know

Stock futures mixed amid energy rally, Pelosi sets Thursday vote on $1 trillion infrastructure bill; Oil prices hit 3-year high near $80 a barrel; Germany elections fail to deliver Merkel's successor; Wall Street week ahead.